Context.-Flexible working at diverse or remote sites is a major advantage when reporting using digital pathology, but currently there is no method to validate the clinical diagnostic setting within digital microscopy.
Results.-In total, 53 experiments were conducted across all phases resulting in 7632 test images viewed in all. Results indicated that the display, the user's visual system, and the environment each independently impacted performance. Performance was improved with reduction in natural light and through use of medical-grade displays.
Conclusions.-The use of a POUQA tool for digital microscopy is essential to afford flexible working whilst ensuring patient safety. The color-contrast test provides a standardized method of comparing diagnostic settings for digital microscopy. With further planned development, the color-contrast test may be used to create a ''Verified Login'' for diagnostic setting validation.
(Arch Pathol Lab Med. doi: 10.5858/arpa.2018-0210-OA) O ne of the most cited advantages of making pathologic diagnoses digitally, using whole slide images viewed on a computer display, is the ability to work flexibly. 1 Recently, the Royal College of Pathologists and Cancer Research UK have actively encouraged Trusts within the United Kingdom to permit flexible working in order to retain senior pathologists. 2 However, despite this, the involvement of digital microscopy in clinical diagnostic work has been hindered. One barrier concerns image fidelity, that is, pixels on the computer display may not accurately depict the tissue seen through the microscope, leading to erroneous diagnoses and patient harm. 3 Unfortunately, flexible working will inevitably introduce further image fidelity concerns due to the unknown safety implications of providing diagnoses in highly variable diagnostic settings. A way to resolve this issue would be to develop a method of validating the whole diagnostic setting (incorporating the display, the user's visual system, and the environment) before making digital diagnoses.
Without a method of validating the whole diagnostic setting, we believe there are 2 possible outcomes regarding flexible working. The first possibility would be to leave it up to the pathologist to make an arbitrary decision regarding the appropriateness of the diagnostic setting. Whilst there are merits to this option, there are situations in which pathologists may not be aware of a compromised diagnostic setting, particularly when digital microscopy is newly introduced. The second possibility is to impose restrictions on flexible working, which may result in reduced retention of more senior pathologists and potentially increased equipment and site costs; it may be that all pathologists can make safe diagnoses only on medical-grade displays in a room with fixed ambient lighting, or it may transpire that some pathologists could diagnose appropriately on a lowergrade display outside of the hospital setting.
This issue has already been addressed by digital radiologists. Concerns over image fidelity has led to extensive research into the production of quality assurance measures to ensure that displays for primary diagnosis achieve minimum performance levels. [4] [5] [6] However, since these checks are not done before every diagnostic session, there is the possibility that diagnostic sessions are taking place that are not appropriate for diagnosis. A digital radiologist may be able to make safe diagnoses in the presence of natural light during a cloudy day, but may need to make adaptations in the presence of bright sunshine to ensure that the diagnostic setting is still meeting minimum requirements.
To solve this issue, our group has previously developed the first Point-Of-Use Quality Assurance (POUQA) tool for digital radiology, 7 which is a method that validates the diagnostic setting before every use (Figure 1 ). The user must complete a short psychometric test or ''Verified Login'' requiring a challenge response by entry of 4 grey letters superimposed on a grey background before the images are viewed. Each letter represents a 5% contrast difference from the background, in accordance with minimum requirements. 4 If the letters are entered incorrectly, the diagnostic setting is not suitable (as the user cannot discern the 5% contrast difference) and therefore the user is not permitted access to the digital scans, preventing potentially aberrant diagnoses from being made. If the letters are entered correctly, the diagnostic setting is suitable (as the user can discern the 5% contrast difference) and the user is therefore permitted access to make safe diagnoses. This Verified Login has been operational within our hospital for many years.
Owing to the intrinsic need for subtle color discernment to make pathologic diagnoses using colored histochemical stains, the digital radiology POUQA tool is understandably not suitable to validate diagnostic settings for digital microscopy. Therefore, the aim of this work is to describe the development of a preliminary POUQA tool specifically for digital microscopy, with an initial evaluation of its clinical use.
METHODS

POUQA Tool Design
The first step in the design of the digital pathology POUQA tool was to select the color that would be used. It is crucial that the color used within the tool be appropriate for the task, since visual sensitivity varies across color space. 8 Since 79% of histopathological diagnoses are made by using hematoxylin-eosin (H&E) in our institution, 9 we chose to use the color of H&E within the POUQA. In previous work we have investigated the color spectra of H&E 9 through systematically staining 200 tissue slides by using eosin alone, hematoxylin alone, and then H&E combined. A total of 300 to 400 measurements of 0.5-lm diameter were taken per slide to fully encompass the gamut. These spectral measurements for hematoxylin only, eosin only, and H&E demonstrated that both hematoxylin and eosin are combined in simple addition to make H&E, rather than chemically interacting to create a different color. 9 To create a linear color scale of H&E (Figure 2 ) comparable to a grey scale in digital radiology, we systematically stained a biopolymer that could be stained with H&E like real tissue.
Using these colors, we designed test images consisting of a random letter superimposed over a uniform background square measuring 5 cm 3 5 cm. We decided to use the darkest H&E red, green, and blue (RGB) value as the background containing a subtly lighter color letter for these preliminary assessments, as crucial diagnostic information is often obtained in regions of the slide that are intensely stained, for example, in the assessment of subnuclear detail. However, the finalized 4-test-image ''Verified Login'' version of the POUQA will include 2 test images with a darker letter on a lighter background to ensure that these subtle color differences can be detected bidirectionally.
In the absence of defined minimum standards in digital pathology, we considered the degree of differences in color or ''color-contrast'' within real tissue that would be of clinical relevance.
We chose a good quality H&E-stained whole slide image, scanned at 340 of an adenomatous colorectal polyp with low-grade dysplasia, and selected a region containing adenomatous nuclei that were in focus. The original image is shown in Figure 3 , A. We chose to evaluate a slide containing adenomatous nuclei, since the evaluation of the chromatin distribution within adenomatous nuclei is an important task for pathologists and is heavily reliant on subtle color discernment and therefore was able to inform our choice of color-contrast thresholds, by using clinically relevant parameters.
Using MATLAB R2015a (The MathsWork Incorporated, Natick, Massachusetts), we analyzed this image with respect to delta-E (dE) within a specified region of interest (ROI) of 15 3 15 pixels. dE is the unit introduced by the Commission Internationale de l'Éclairage to quantify the visual change in perception between 2 colors. The smallest perceptual change in color is generally regarded as 1 dE, with 2 to 10 dE being perceptible at a glance, Figure 1 . This is a demonstration of the ''Verified Login'' for digital radiology used within Leeds Teaching Hospitals National Health Service (NHS) Trust, Leeds, United Kingdom. The user must correctly identify each of the 4 letters before being able to access the digital scans. Each letter is 5% contrast difference from the background grey scale. Figure 2 . A linear color scale for hematoxylin-eosin created by using the stained biopolymer.
11-to 49-dE colors being more similar than opposite, and 100 dE representing exact opposite colors. 10 An ROI of 15 3 15 pixels was chosen as it equated to an approximate width of the adenomatous nuclei, which is large enough to provide local context within the ROI; an area of this size would likely be needed by pathologists to provide their assessment of the chromatin pattern within these nuclei. However, because it is not possible to accurately quantitate an ROI that is reflective of that which pathologists use when performing their assessment, Figure 2 should be considered as illustrative of how changing the dE threshold affects visualization of features.
The white areas within Figure 3 , A through D, are those with a dE difference from the mean within the ROI, below a specified threshold. By a dE threshold of 2, a great proportion of the nuclear pixels are below these thresholds (ie, white). If a diagnostic setting did not enable the pathologist to discern 2 dE, then this nuclear detail would not be discernible, which may impact diagnosis in this diagnostically challenging area.
As mentioned previously, we were able to use this information to inform the generation of 8 color-contrast levels with varying dE. The chosen range included a dE of 1, as this is generally regarded as synonymous with a ''just noticeable difference,'' and the results in Figure 3 , A through D, show that there is loss of nuclear detail already by this threshold. A just noticeable difference is the smallest amount by which a stimulus is changed in order for it to be perceptible. The test images, each including a letter varying from the background color by incremental steps in dE, were saved in the PNG file format since PNG files are supported by most Web browsers and allow cross-platform color consistency, and degradation in image quality is avoided by lossless compression.
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Examples of the test images at each of the color-contrast levels by dE can be seen in Figure 4 , A through H.
Eighteen test images were created per color-contrast level to create 144 test images, a sufficient number of test images to ensure that participants avoid memorizing the correct responses.
A Web-based experiment platform, Prospector, 12 was used for the preliminary test environment ( Figure 5) . A grey scale reference Figure 3 . A through D, The effects of changing the delta E threshold on interpretation of whole slide images. A, The original image showing adenomatous nuclei with low-grade dysplasia within an adenomatous colorectal polyp. B, Image analyzed with a delta E threshold of 0.5. C, Image analyzed with a delta E threshold of 1. D, Image analyzed with a delta E threshold of 2. The white areas are those areas with a mean delta E of less than the specified threshold. As the threshold increases, the areas within the whole slide image, which are affected dramatically, increase; by a delta E threshold of 2, much of the color subtleties within the nucleus are lost. An inability to detect these subtleties may influence diagnosis in these diagnostically challenging areas that rely heavily on color assessment. chart was included in the briefing to enable the user to calibrate the brightness and contrast range of the computer display setting. 4 Each of the 144 test images were displayed individually and in random order. The participant viewed each image before inputting the letter seen, using the keyboard. There was no imposed time limit. All responses were treated as either correct or incorrect. Participants could ''skip'' images rather than forcing a letter response. A skipped image was treated as incorrect. Participants could also go back and correct a response.
Tool Evaluation
The preliminary POUQA tool was evaluated across 2 institutions in 3 phases. Phase 1 involved a circulatory email sent to National Health Service (NHS) staff in the Pathology and Medical Physics departments at St James's University Hospital in Leeds, United Kingdom. The experiments in phase 1 were unobserved and the diagnostic setting was not recorded.
Phase 2 occurred in Department of Clinical Pathology at Linköping University Hospital, Linköping, Sweden, which is currently using digital microscopy for primary diagnosis with medical-grade displays. 13 Experiments in phase 2 were opportunistically sampled and observed in the natural diagnostic setting, that is, participants were asked not to alter display, viewing conditions, ambient lighting, or make other changes. The display was recorded.
Phase 3 took place in Leeds Teaching Hospitals NHS Trust. Again, participants were opportunistically enrolled, and all experiments were observed. The diagnostic setting, including the participant, display type, and the environmental set-up, was recorded. Display categories (with typical display specifications as new) were recorded as follows: In the presence of natural light, the viewing direction of the pathologist with respect to the natural light was recorded as outlined in Figure 6 , A through C.
A standardized participant conducted the same experiments immediately before or after the other participants to allow for interparticipant comparison on the same display in the same diagnostic setting for experiments in phases 2 and 3.
Local ethical approval for this work was obtained from Leeds West LREC 10-H1307-12 in the United Kingdom and departmental approval was obtained in Sweden.
RESULTS
Phase 1
Phase 1 experiments were carried out for 10 days, with 11 experiments performed by 11 participants. The median score for the lowest dE (0.56) was 0% (0 of 18), with scores rising sharply to 100% (18 of 18) by the highest dE (1.77) ( Figure  7 ). 
0.56) was 0%, meaning that, on average, the letter at this delta E was not discernible. However, by a delta E of 1.0, the median score was 100%, indicating that the letter at this delta E could be reliably seen. When analyzed by participant (Figure 8 ), the median score was 71.5% (103 of 144), with a wide range of 38.8% (56 of 144) and an IQR of 22.6% (33 of 144).
Phase 2
In this phase, 16 experiments were conducted by 6 participants for 3 days in Sweden. Eleven experiments were conducted on the same-brand medical-grade displays used for primary diagnosis. The median score for the lowest dE (0.56) was 0% (0 of 18), with scores rising sharply to a median score of 100% (18 of 18) by a dE of 0.75. The overall performance from phase 2 is compared to that of phase 1 in Figure 9 .
When analyzed by participant, the median score was 86.8% (125 of 144), with a range of 22.9% (33 of 144) and an IQR of 1.4% (2 of 144), which is an improvement on the median score from phase 1 by 15.3% (22 of 144). The results for the 11 experiments completed by consultants who report using their medical-grade displays are shown in Figure 10 .
During these experiments, the displays were positioned at an angle of 908 to a large window. There were no blinds drawn; however, some of the experiments were performed after the sun had set. The performance of 1 individual (depicted in the long dashed line) was worse than that of the other participants, particularly at lower dE levels. The results for this participant when compared to the control participant on the same display in the same environment were markedly different (Figure 11 ), indicating that the user was underperforming at the test, as opposed to implicating the display or the environmental conditions. On discussion with the participant in question, an ophthalmic issue was noted as was the fact that the participant was currently receiving treatment.
Phase 3
In Phase 3, a total of 26 experiments were performed by 6 participants on a range of different display types in a range of environments. As depicted in Figure 12 , the median score for the lowest dE (0.56) was 0% (0 of 18), with scores rising to 100% (18 of 18) by a dE of 0.78.
When analyzed by participant, the median score was 80.6% (116 of 144), with a range of 81.3% (117 of 144) and an IQR of 25.9% (37 of 144). When the participant was standardized, the best median score was obtained by medical-grade displays (87.5%, 126 of 144) and the worst from older standard departmental desktop displays (71.5%, 103 of 144), as can be seen in Figure 13 , A. This equates to a median improvement in overall score of 16% (23 of 144). This pattern is reflected when extending the scores to include all participants (Figure 13, B) .
To investigate the degree of influence of natural light on performance, the experiment was repeated by a participant who had scored only 34.7% (50 of 144) on the old NHS desktop display. This participant carried out a further experiment on a laptop with the window behind the display. This resulted in a particularly poor performance of just 11.8% (17 of 144). Immediately afterwards, a black-out blind was placed up at the window and the experiment was repeated with artificial light on the same laptop by the same participant. This resulted in a score of 85.4% (123 of 144), an increase in performance of 73.6% (106 of 144), as shown in Figure 14 .
The control participant conducted experiments in a range of different ambient light settings, using the same laptop display, with results shown in Figure 15 . Performance was best with just artificial lighting and no natural light (93.0%, 134 of 144), then with the window behind the pathologist (86%, 124 of 144), and then with the window 908 to the display (77.9%, 112 of 144). The worst performance was with the window behind the display (73.5%, 106 of 144).
DISCUSSION
As pathology departments around the world turn to digital pathology for primary reporting, it is essential that there be quality assurance strategies in place to protect patients and other stakeholders. Unlike other quality assurance methods widely used in digital radiology, a POUQA tool enables validation of the whole diagnostic setting (display, the user's visual system, and the environment), rather than just 1 component. Moreover, in a health care system of high demand yet very limited resources, cost savings that do not compromise patient safety are crucial. Once guidelines regarding minimum requirements of the display for digital pathology are published and pathologists start taking advantage of flexible working, a POUQA tool will enable the use of any display in any environment, so long as minimum standards are met. The most important finding repeated in all phases of our initial evaluation of the tool is the wide range in performances when carrying out the color-contrast test within 2 histopathology departments, due to variations in the display, the participant, or the environment. Without a POUQA tool for digital pathology, this variation in performance would not be apparent and its significance unknown.
Our phase 2 and 3 results have enabled us to demonstrate that the user, the display, and the environment each have an influence on overall performance. Moreover, pathologists may be able to modify performance through changes to the display and/or the environment, as indicated by a 73.6% increase in performance with the simple modification of a black-out blind at the window and the use of artificial lighting. The use of an immediate repeat by the same participant, on the same display, isolated the effect of the environment on the results and prevented confounding from other variables (user and display).
However, we are aware that the user, the display, and the environment are not independent of one another. Technical specifications of the displays, including the reflection coefficient and the luminance, will influence how the environment impacts performance.
14 Our results support this concept, since there were multiple performances in phase 2 with scores above 80% on medical-grade displays in an environment with a large amount of natural light, as compared to several performances with scores below 60% on old NHS hospital-owned desktop displays in similar environments. Nevertheless, in the absence of a POUQA tool to assess performance, our findings support the need to control ambient light when using digital pathology for primary diagnosis, in accordance with existing International Color Consortium recommendations.
15 It should also be remembered that most display manufacturers recommend that displays not be placed in direct sunlight.
A further interesting finding from this work was the identification of a user with an ophthalmic problem through use of a color-contrast test. Again, the use of an immediate repeat by a control participant prevented any change in the other 2 variables (environment and display), which would confound the results. This may seem initially alarming to pathologists; however, pathologists' ability to diagnose Figure 10 . Scores for phase 2 per consultant participant on their respective diagnostic displays for each delta E. Each line represents the score for 1 participant. The scores of 1 participant were markedly worse than the others. Figure 11 . Scores for the control participant as compared to the participant who had performed comparatively poorly at the test. The discrepancy in the scores highlights that the reason for the underperformance was due to the user's visual system and not the display or the environment. Figure 12 . Median scores for all phases by delta E. The overall median score for phase 3 was 80.6% (116 of 144), which is a reduction in performance of 6.2% (9 of 144) as compared to phase 2, but an improvement in performance as compared to phase 1 of 9.1% (13 of 144). correctly and in accordance with others for the safety of patients is extensively evaluated in the United Kingdom through postgraduate examinations and external quality assurance processes. It is not dissimilar to involve the evaluation of the user's visual system in a quality assurance process for the aim of patient safety. Moreover, we have demonstrated that amendment of the diagnostic setting either through changes to the display or the environment can significantly impact performance and therefore we would argue that awareness of one's limitations (particularly when there are measures that can be taken to improve performance) should be considered a benefit both to patients and pathologists. Furthermore, the POUQA test could enable further self-awareness, by being used during and immediately after long review sessions to assess the effects of asthenopia and increased myopia. 16 Whilst the age of the pathologists involved in the evaluation was not recorded, it is certain that age will impact performance. It is well known that the human visual system is affected by aging with decrease of color vision, with colors appearing to be more ''washed out'' with age. 10 Again, we would argue that increased self-awareness of one's limitations is a considerable benefit and enables pathologists to take actions to counteract these effects, by modifying either the display or the environment.
Our initial evaluation also included a participant with a common color vision deficiency. This participant performed well with an overall score of 87%. This finding is reassuring, given that our POUQA does not appear to unfairly disadvantage those with color vision deficiencies.
To the best of our knowledge, this work represents the first attempt to create a POUQA tool for digital microscopy and therefore the major strength of this work lies in the fundamental concept of validating the diagnostic setting with the main aim of ensuring patient safety. We are similarly unaware of any such tool that enables the technical evaluation, which includes the human reader, and is not currently encompassed by the US Food and Drug Administration's current regulatory framework.
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A further key strength is in the rigorous methodology required to ensure that our color-contrast test was suitable for the task; extensive evaluation of H&E spectra was required to inform the creation of the test images. Additionally, the use of 144 randomized image squares each containing 1 letter out of a potential 26 per experiment resulted in the evaluation of a large number of test images (7632) within this initial work and prevented participants from being able to ''learn'' the answers. The percentage obtained through random guessing would be 1/26 ¼ 4% and therefore, we can be confident that the results obtained are due to participants seeing the letter within the test images.
Whilst the findings of this work are very intriguing, there are several limitations to both the development and initial evaluation. Firstly, with regard to the tool development, the use of letters in a POUQA tool is a simple way of checking color-contrast assessment, but errors can occur by accidentally inputting the wrong letter or by confusing letters of similar shape, such as ''Q'' and ''O.'' However, it could equally be argued that these subtle features would be advantageous for determining response to subtle morphologic features. More work needs to be done to determine the impact of letter choice but in the interim using a full range of the alphabet is recommended. Additionally, a POUQA tool will not preclude the use of behaviors to try and improve performance. For instance, placing hands around the letters on the screen to block out natural light and changing the viewing angle both can manipulate the contrast. 18 Also, viewing the image longer than intended will take advantage of the human visual system's adaptive qualities by increasing the viewer's contrast sensitivity, so may affect the result. 19 The range of color-contrast levels included in this work was generated in the absence of guidance regarding minimum performance levels. Whilst we made an attempt to try to keep the color-contrast levels of clinical importance, a full evaluation as to the diagnostic significance of the colorcontrast levels was beyond the scope of this initial work and therefore the color-contrasts may need to be amended. Adenomatous polyps were chosen in this initial assessment, as diagnosis of dysplasia is a common and difficult area of pathology, with a high level of disagreement between pathologists, and there is known color-contrast importance. However, it should be noted that other pathologic entities may have a greater or lower requirement for contrast sensitivity. Nonetheless, a dE of 1, that is, just perceivable color difference, would appear to be a practical threshold and before further work is conducted to refine these thresholds, a default threshold of 1 dE is recommended. It should be remembered that direct comparisons regarding the radiology POUQA tool (Figure 1 ) and the pathology POUQA tool cannot be made, as the radiology tool is based on percentage contrast of grey scale and the pathology tool uses dE as a perceptual index of color difference. However, the key similarity between these tools relates to the use of thresholds of clinical significance.
Despite the large number of test images included within this initial evaluation, the small number of participants involved and the opportunistic sampling methodology limit the conclusions that can be derived from this work. Therefore, we plan to extend our initial evaluation with a larger sample, using an improved sampling strategy. We also plan to use the color-contrast tool to investigate the optimum display settings to elicit the best performance; similar settings may be preferable for all individuals or there may be variations. To create a fully operational Verified Login for digital microscopy, the full 144 test image colorcontrast test will need to be amalgamated into 4 test images. We may also investigate the possibility of including other stains in the POUQA tool.
Once this methodology is validated, a routine QA tool can be developed and implemented at the point of use, regardless of setting, to provide clinical assurance on the suitability of the setting, display, and the user for this specific task.
CONCLUSIONS
To the best of our knowledge, this work outlines the development and initial evaluation of the first POUQA tool developed for digital microscopy. Within this initial work, we have produced a consistent method of comparing diagnostic settings within histopathology departments and with further development of a ''Verified Login,'' it may be used for validation purposes. This would enable pathologists to take full advantage of flexible working, whilst facilitating the use of any display and any environment so long as minimum standards are met. Without use of a POUQA tool, pathologists will remain unaware of the limitations of a diagnostic setting and will be unable to determine when a diagnostic setting is unsuitable for diagnosis.
